Abstract

INTRODUCTION. The introduction of non-natural amino acid residues or modules into proteins enables the study of the significance of single amino acid residues or entire structural regions in the stability of the protein, its folding/unfolding behavior, or its biological function. Bovine pancreatic ribonuclease A (RNase A) is a small protein with a well-characterized structure and thoroughly studied stability and unfolding/folding behavior (1). More recently, RNase A also became a target of studies as a chemotherapeutic (2). We exploited the method of intein-mediated protein ligation (3) to introduce non-natural amino acid residues into the C-terminal part of RNase A and investigated the biochemical properties of the variants. METHOD. Peptides containing either the wild-type RNase A sequence Cys95-Val124 or the same sequence with replacements for certain amino acid residues were synthesized by solidphase methods. Full-length RNase A or RNase A 1-94 and variants of these were produced as a fusion protein. The respective DNA sequence was inserted into the plasmids pTYB1 and pTXB1 to produce a fusion protein, which consists of RNase A (1-124 or 1-94) with an additional Met –1, the intein, and a chitin-binding domain (4). RESULTS. With pTYB1, purification of the fusion protein and thiol-facilitated formation of a thioester at the C-terminal Asn94 of the RNase A 1-94 fragment resulted in high amounts of cleavage product. However, only a little fraction contained the required thioester due to the slow intein cleavage and the fast thioester hydrolysis. Ligation of the intein cleavage product with the corresponding peptide yielded about 70 µg of ligation product per liter of bacterial culture. An N94A RNase A 1-94 variant proved to result in considerable higher yields of thioester, enabling efficient ligation of the protein component with the peptide. Here, ligation yielded about 200 µg of product per liter of bacterial culture. With pTXB1, the yields of fusion protein were substantially higher which allowed a formation of ligation product in reasonable amounts.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.